The first 60 days: POLE-ultramutated endometrial cancer
POLE-ultramutated endometrial cancer carries a fault in the proofreading part of a DNA-copying enzyme, so its cells pile up enormous numbers of mutations. It looks aggressive under the microscope yet almost never comes back after surgery, so trials are testing whether radiotherapy and chemotherapy can be dropped altogether. Below, week by week, is what OnCo's record of POLE-ultramutated endometrial cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Hysterectomy with bilateral salpingo-oophorectomy and sentinel node mapping; molecular classification of every endometrial cancer with POLE sequencing, MMR and p53 immunohistochemistry.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Diagnosis and classification.
- SurgeonNamed in the standard of care for: Diagnosis and classification.
- Medical oncologistNamed in the standard of care for: Stage I to II after surgery, Stage III after surgery, Advanced or recurrent (rare).
- Clinical oncologist (radiotherapy)Named in the standard of care for: Stage I to II after surgery, Stage III after surgery.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Observation without adjuvant treatment is acceptable under the ESGO/ESTRO/ESP guideline; vaginal brachytherapy where local protocol still requires it.
Pelvic radiotherapy without chemotherapy, as in RAINBO POLEmut-BLUE; chemoradiation with chemotherapy remains an option outside trials.
Checkpoint inhibitor with or without chemotherapy by extrapolation from the mismatch-repair-deficient class.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example POLE exonuclease domain sequencing, Tumour mutational burden above 100 mutations per megabase, p53 and MMR immunohistochemistry, Tumour-infiltrating lymphocytes, Stage and lymphovascular space invasion), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include POLE exonuclease domain hotspot mutation, POLE-ultramutated with secondary p53 or MMR abnormality, Stage I to II POLE-ultramutated.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Diagnosis and classification
- For my situation (diagnosis and classification), which of the standard options do you recommend and why?Guideline options include: Hysterectomy with bilateral salpingo-oophorectomy and sentinel node mapping; molecular classification of every endometrial cancer with POLE sequencing, MMR and p53 immunohistochemistry.
- How do the results of FIRES & SENTOR (sentinel node mapping) apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Stage I to II after surgery
- For my situation (stage i to ii after surgery), which of the standard options do you recommend and why?Guideline options include: Observation without adjuvant treatment is acceptable under the ESGO/ESTRO/ESP guideline; vaginal brachytherapy where local protocol still requires it.
Stage III after surgery
- For my situation (stage iii after surgery), which of the standard options do you recommend and why?Guideline options include: Pelvic radiotherapy without chemotherapy, as in RAINBO POLEmut-BLUE; chemoradiation with chemotherapy remains an option outside trials.
- Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of PORTEC-3 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Advanced or recurrent (rare)
- For my situation (advanced or recurrent (rare)), which of the standard options do you recommend and why?Guideline options include: Checkpoint inhibitor with or without chemotherapy by extrapolation from the mismatch-repair-deficient class.
- Am I a candidate for Pembrolizumab, Dostarlimab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Molecular-class-directed adjuvant therapy in endometrial cancer, Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP), MRD / molecular residual disease testing?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Deciding which non-hotspot POLE variants are pathogenic”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Whether stage III and IV disease can also be de-escalated”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- POLE-ultramutated endometrial cancer: the full pagePOLE-ultramutated endometrial cancer carries a fault in the proofreading part of a DNA-copying enzyme, so its cells pile up enormous numbers of mutations. It looks aggressive under the microscope yet almost never comes back after surgery, so trials are testing whether radiotherapy and chemotherapy can be dropped altogether.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Next-generation sequencing (NGS): Reading millions of DNA fragments in parallel, the engine behind every modern genomic test.
- Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP): Four groups defined by a few tests that predict outcome better than the microscope: POLE-mutated (excellent), mismatch-repair deficient, p53-abnormal (worst), and 'no specific profile'.
- Hysterectomy: Removing the uterus (womb), often with the cervix, tubes and ovaries.
Every term links to the glossary.